



The Advances of Cold Plasma in the Biomedicines 2.0

Guest Editor:

Prof. Dr. Gyocheon Kim

Department of Oral Anatomy,
School of Dentistry, Pusan
National University, Yangsan
50612, Korea

Deadline for manuscript
submissions:

closed (15 April 2023)

Message from the Guest Editor

Plasma used in industrial fields requires a vacuum state and can generate high heat. When the temperature of the plasma is less than 250 degrees Celsius, it is called low-temperature plasma. In order to be treated on human tissues, the temperature of the plasma must be less than 40 degrees Celsius. In that respect, it has recently been referred to as cold plasma. Plasma medicine, which started when cold plasma was applied to bacteria and cells, has made considerable progress over the past 20 years. The scope of plasma research has expanded from just killing pathogens and cancer cells to tissue regeneration and selective cancer cell death. In the current research climate, this Special Issue calls for advanced plasma medicine research results by not only explaining various life phenomena induced by plasma, but also cellular or histologic mechanisms. The scope of the research subject is limited to bacteria living in animals, animal cells and tissues, and biomaterials that can be inserted into the human body. Experimental papers and review papers consistent with this research topic are both eligible.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)